FDA Approves Tecentriq Plus Chemotherapy for Stage III dMMR Colon Cancer

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with fluoropyrimidine and oxaliplatin chemotherapy for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer. This marks the first approved immunotherapy-based adjuvant treatment regimen for this patient population, offering a new option for patients at high risk of disease recurrence. The approval is supported by the phase III ATOMIC trial, which showed a 50% reduction in the hazard of disease recurrence or death with atezolizumab plus chemotherapy compared to chemotherapy alone.